scholarly journals EFFECT OF LIFESTYLE MODIFICATION IN TYPE II DIABETES MELLITUS INDIVIDUALS

2019 ◽  
pp. 381-383
Author(s):  
AVANI BHOSALE ◽  
POOVISHNU DEVI THANGAVELU
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Exercise Tolerance ◽  
Lifestyle Modification ◽  
Density Lipoprotein ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Group A ◽  
Conventional Physiotherapy ◽  
Group B

Objectives: The objectives of this study were as follows: (1) To find the effect of conventional physiotherapy along with medications on Type II diabetes mellitus (DM) individuals and (2) to find the effect of lifestyle modification (LSM) and conventional physiotherapy with medications on Type II DM individuals. Methods: Ethical clearance was obtained from the institutional ethical committee. A total of 70 Type II DM individuals were assessed and 64 were included in this study based on inclusion criteria, the individuals were allocated into two groups: Group A (n=32) received conventional physiotherapy along with prescribed diabetic medications and Group B (n=32) received LSM and conventional physiotherapy with prescribed diabetic medications. Pre- and post-test were done for plasma glucose, serum insulin, glycated hemoglobin (HbA1c), total cholesterol, triglycerides, high-density lipoprotein-C, low-density lipoprotein by blood test, exercise tolerance by 6-min walk test, and quality of life (QOL) by SF-36 questionnaire, and the outcome measures were analyzed after 3 months. Results: Intergroup statistical analysis for HbA1c (p<0.0001) and QOL (p<0.0001) revealed extremely significant difference post-intervention. Analysis of HbA1c test for Group A (p=0.0652) was not significant and for Group B (p<0.0001) was extremely significant. Moreover, QOL was significant for Group A (p=0.0004) as well as for Group B (p<0.0001). Conclusion: The study results concluded that LSM was significantly effective in reducing HbA1c levels, exercise tolerance, plasma glucose, serum glycerine, and total cholesterol and improving QOL compared to conventional exercise.

scholarly journals Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer

2018 ◽  
pp. 1-10 ◽  
Author(s):  
Amal Al Omari ◽  
Hadeel Abdelkhaleq ◽  
Maysa Al-Hussaini ◽  
Rim Turfa ◽  
Nour Awad ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Colorectal Cancer ◽  
Overall Survival ◽  
Type Ii Diabetes ◽  
Progression Free Survival ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Free Survival ◽  
Group A ◽  
Group B

Purpose Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients with colorectal cancer (CRC) and type II diabetes mellitus (DM). Although type II DM and CRC are major health problems in the Middle East, no investigations have been performed to test the effect metformin has on the outcome of patients with type II DM and CRC who are also treated with metformin. Materials and Methods We retrospectively reviewed the medical records of 1,902 patients diagnosed with CRC at King Hussein Cancer Center between January 2004 and December 2012, and identified 349 patients (18%) with type II DM; we censored the data of 28 patients because their antidiabetic medications were unknown. We then categorized these 321 patients into two groups: 192 patients treated with metformin (group A) and 129 patients treated with other antidiabetic medications (group B). Results Group A patients had significantly longer overall survival (89 months; 95% CI, 66 to 112 months) and progression-free survival (47 months; 95% CI, 15 to 79 months) than group B patients (overall survival: 36 months; 95% CI, 24 to 48 months; P ≤ .001; progression-free survival: 21 months; 95% CI, 13 to 29 months; P = .016). After adjustment for age, sex, body mass index, aspirin use, anticholesterol treatment, and CRC stage, group A patients had a 40% reduction in mortality (hazard ratio, 0.58; 95% CI, 0.4% to 0.85%; P = .005). Conclusion Our results support findings from other populations that patients with diabetes and CRC who are also treated with metformin have better outcomes than those treated with other antidiabetic medications.

scholarly journals Synergistic Hypoglycemic Effects of Pumpkin Polysaccharides and Puerarin on Type II Diabetes Mellitus Mice

Molecules ◽  
2019 ◽  
Vol 24 (5) ◽  
pp. 955 ◽  
Author(s):  
Xue Chen ◽  
Lei Qian ◽  
Bujiang Wang ◽  
Zhijun Zhang ◽  
Han Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Type Ii Diabetes Mellitus ◽  
Hypoglycemic Effect ◽  
Lipid Lowering ◽  
Heme Oxygenase 1 ◽  
Related Factor ◽  
Type Ii

To investigate the hypoglycemic effect and potential mechanism of pumpkin polysaccharides and puerarin on type II diabetes mellitus (T2DM) mice, mice were fed a high-fat diet and injected intraperitoneally with streptozotacin to induce T2DM. After eight weeks of drug administration, blood samples were withdrawn from tail veins of mice that had been fasted overnight. The results showed that both pumpkin polysaccharides and puerarin, as well as a pumpkin polysaccharides and puerarin combination, could ameliorate T2DM. The pumpkin polysaccharides and puerarin combination had a synergetic hypoglycemic effect on T2DM mice that was greater than the pumpkin polysaccharides’ or the puerarin’s hypoglycemic effect. Both the pumpkin polysaccharides and the puerarin were found to ameliorate the blood glucose tolerance and insulin resistance of T2DM mice. They showed lipid-lowering activity by reducing the total cholesterol, triglycerides, and low-density lipoprotein levels, and improving the high-density lipoprotein level. They had beneficial effects on the oxidative stress by decreasing the reactive oxygen species and malondialdehyde levels, and increasing the glutathione level and the superoxide dismutase activity. Furthermore, the nuclear factor E2 related factor 2 (Nrf2), heme oxygenase-1, and phosphoinositide-3-kinase (PI3K) levels were upregulated, and the Nrf2 and PI3K signalling pathways might be involved in the hypoglycemic mechanism. The combined administration of pumpkin polysaccharides and puerarin could synergistically ameliorate T2DM.

scholarly journals Efficacy and adverse reaction to different doses of atorvastatin in the treatment of type II diabetes mellitus

2019 ◽  
Vol 39 (7) ◽  
Author(s):  
Hua Jiang ◽  
Hong Zheng
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Adverse Reactions ◽  
Density Lipoprotein ◽  
Type Ii Diabetes Mellitus ◽  
Retinol Binding Protein ◽  
Type Ii ◽  
Sprague Dawley ◽  
Rat Serum ◽  
Different Doses

Abstract Background: Type II diabetes mellitus (T2DM), a persistent metabolic disorder, is primarily characterized by insulin resistance, relative insulin deficiency and dyslipidemia. Here, we aimed to investigate whether different doses of atorvastatin (ATV) affect rats with T2DM. A total of 110 Sprague–Dawley rats were successfully established as T2DM models. Methods: First, the total cholesterol, triglyceride (TG), high-/low-/very-low-density lipoprotein cholesterol (HDL-c/LDL-c/VLDL-c), alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine (Cr), apolipoprotein Al (ApoA1) and apolipoprotein B (ApoB) levels in rat serum were analyzed. In addition, cholesteryl ester transfer protein (CETP) and retinol-binding protein 4 (RBP4) were also measured. Then, the incidence of adverse reactions was noted. Finally, the pathological study of liver and pancreatic tissues was performed. Results: Rats administered ATV at the doses of 40 and 80 mg/(kg·day) showed down-regulated TG, LDL-c, ApoB, CETP and RBP4 levels yet up-regulated HDL-c and ApoAl levels. Rats administered ATV at a dose of 80 mg/(kg·day) exhibited a higher incidence of adverse reactions and higher ALT and AST levels but lower BUN and Cr levels, which might affect liver and kidney function. Rats administered ATV at the doses of 40 and 80 mg/(kg·day) demonstrated significantly improved liver injury and pancreatic injury induced by T2DM. Conclusion: These data revealed that ATV could improve the lipid metabolism in T2DM rats and 40 mg/(kg·day) may serve as the optimal dose for the reduction of lipid levels and the incidence of adverse effects.

scholarly journals Left ventricular function and exercise tolerance in patients with type ii diabetes mellitus

1998 ◽  
Vol 21 (8) ◽  
pp. 567-571 ◽  
Author(s):  
Luigi Irace ◽  
Diana Iarussi ◽  
Immacolata Guadagno ◽  
Maria Luisa De Rimini ◽  
Luigi Mansi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Left Ventricular Function ◽  
Ventricular Function ◽  
Type Ii Diabetes ◽  
Exercise Tolerance ◽  
Type Ii Diabetes Mellitus ◽  
Left Ventricular ◽  
Type Ii

scholarly journals Evaluation of Serum HDL and LDL levels in Type II Diabetes Mellitus

2013 ◽  
Vol 1 (1) ◽  
pp. 21 ◽  
Author(s):  
K R Joshi ◽  
K K Hiremath ◽  
S P Gupta
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Type Ii Diabetes Mellitus ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Type Ii

  Introduction: Diabetes mellitus is a type of metabolic disorder characterized by hyperglycemia resulting from defect in insulin secretion, insulin action or both. This study intended to compare High Density Lipoprotein Cholesterol (HDL) and Low Density Lipoprotein Cholesterol (LDL) profile between type II diabetic and non-diabetic subjects and also find the correlation between HDL and LDL cholesterol in type II diabetic.   Methods: The study was conducted on 100 total subjects out of which experimental group with 50 subjects of known Type II Diabetes mellitus and control group with 50 subjects.   Results: The result of the present study suggests that fasting blood sugar and LDL cholesterol levels were increased but HDL cholesterol level was reduced in type II diabetic subjects when compared to controls.   Conclusion: The estimation of HDL cholesterol and LDL cholesterol in type II diabetes mellitus is very useful as it may serve as a useful parameter to monitor the prognosis of the patient.

scholarly journals SERUM SIALIC ACID CONCENTRATION AND TYPE II DIABETES MELLITUS

2006 ◽  
Vol 13 (04) ◽  
pp. 508-510
Author(s):  
MOHAMMAD JAWAID SABZWARI ◽  
MUKHTAR AHMAD ◽  
MUHAMMAD TAHIR MAJEED ◽  
Muhammad Riaz ◽  
Muhammad Umair
Keyword(s):  
Diabetes Mellitus ◽  
Sialic Acid ◽  
Type Ii Diabetes Mellitus ◽  
Control Group ◽  
Diabetic Patients ◽  
Type Ii ◽  
Serum Triglycerides ◽  
Serum Sialic Acid ◽  
Group A ◽  
Group B

Sialic Acid (SA) is an acetylated product of neuraminic acid. In presentstudy, the relationship between sialic acid and type II diabetic patients was investigated. Ninety (90) subjects, 41 malesand 49 females, were included in the study. They were divided into two groups according to presence or absence oftype II diabetes mellitus (DM). Group A comprised of 72 patients with type II DM and group B 18 subjects withoutdiabetes mellitus as a control group. The following parameters were assessed: sialic acid, blood glucose, lipid profile(serum triglycerides and total cholesterol) and HbA1c. Type II DM Patients had higher levels (P<0.05) of sialic acid(2.259±0.252 mmol/L) as compared to the control group (2.048±0.32 mmol/L).

Sign in / Sign up

Export Citation Format

Share Document